

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/609,207
		Filing Date	June 26, 2003
		First Named Inventor	Lada Rasochova
		Art Unit	1638
		Examiner Name	(not yet assigned)
		Attorney Docket Number	WARF-100XCD1
Sheet	1	of	4

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
BB	U1	US- 5,863,716	12-29-1998	TATTERSALL et al.	
	U2	US- 5500380	03-10-1998	AHLQUIST et al.	
	U3	US- 5418153	05-23-1995	MORI et al.	
	U4	US- 5824856	10-20-1998	MORI et al.	
	U5	US- 5,861,767	12-22-1998	OLIVO et al.	
	U6	US- 5,817,512	10-06-1998	MORROW et al.	
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	MM-DD-YYYY		
	F1				
	F2				
	F3				
	F4				
	F5				
	F6				
	F7				
	F8				
	F9				
	F10				

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 10 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08U (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

*Complete if Known*

Application Number	10/609,207
Filing Date	June 26, 2003
First Named Inventor	Lada Rasochova
Group Art Unit	1638
Examiner Name	(not yet assigned)
Attorney Docket Number	WARF-100XCD1

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Citation No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BB	R1	VERCHOT et al., <i>J. of Virology</i> (1995), 69(6): 3668-3674
	R2	ALLISON et al., <i>J. of Virology</i> (1988), 62(10): 3581-3588
	R3	FONTES et al., <i>The Plant Cell</i> (1994), 6: 405-416
	R4	BERGLUND et al., "Enhancing immune responses using suicidal DNA vaccines", <i>Nature Biotech.</i> (1998), 16: 562-565
	R5	DE JONG and AHLQUIST, "A hybrid plant RNA virus made by transferring the noncapsid movement protein from a rod-shaped to an icosahedral virus is competent for systemic infection", <i>Proc. Natl. Acad. USA</i> (1992), 89: 6808-6812
	R6	DINANT et al., "Bromovirus RNA replication and transcription requires compatibility between the polymerase- and helicase-like viral RNA synthesis proteins", <i>J. Virol.</i> (1993), 67: 7181-7189
	R7	DZIANOTT and BUJARSKI, "Derivation of an infectious viral RNA by autolytic cleavage of <i>In vitro</i> transcribed viral cDNAs", <i>Proc. Natl. Acad. Sci. USA</i> (1989), 86: 4823-4827
	R8	EDWARDS, "Mapping of the seed transmission determinants of barley stripe mosaic virus", <i>MPMI</i> (1995), 8: 906-915
	R9	FRENCH and AHLQUIST, "Characterization and engineering of sequences controlling <i>In vivo</i> synthesis of brom mosaic virus RNA3", <i>J. Virol.</i> (1988), 62(7): 2411-2421
	R10	HEMENWAY et al., "Characterization of infectious transcripts from a potato virus X cDNA clone", <i>Virology</i> (1990), 175: 365-371
	R11	ISHIKAWA et al., "In Vivo DNA expression of functional brom mosaic virus RNA Replicons in <i>Saccharomyces cerevisiae</i> ", <i>J. of Virology</i> (1997), 71(10): 7781-7790
	R12	JACKSON and HUNTER, "Hordeivirus relationships and genome organization", <i>Annu. Rev. Phytopathol.</i> (1989), 27: 95-121
✓	R13	JANDA et al., "High efficiency T7 polymerase synthesis of infectious RNA from cloned brom mosaic virus cDNA and effect of 5' extensions on transcript infectivity", <i>Virology</i> (1987), 158: 259-262

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1410B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>
Sheet	3	of	4	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number
				10/609,207 June 26, 2003 Lada Rasochova 1638 (not yet assigned) WARF-100XCD1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BB	R14	KAIDO et al., "Inhibition of bromo mosaic virus (BMV) amplification in protoplasts from transgenic tobacco plants expressing replicable BMV RNAs", <i>J. of Gener. Virology</i> (1995), 76: 2827-2833	
	R15	ISI IIKAWA et al., "Yeast mutations in multiple complementation groups inhibit bromo mosaic virus RNA replication and transcription and perturb regulated expression of viral polymerase-like gene" <i>PNAS</i> (1997), 94: 13810-13815	
	R16	LEWANDOWSKI and DAWSON, "Deletion of internal sequences results in tobacco mosaic virus defective RNAs that accumulate to high levels without interfering with replication of the helper virus", <i>Virology</i> (1998), 251(2): 427-437	
	R17	RASOCHOVA and MILLER, "Satellite RNA of barley yellow dwarf-RPV virus reduces accumulation of RPV helper virus RNA and attenuates RPV symptoms on oats", <i>Molecular Plant-Microbe Interact</i> (1998), 9: 648-650	
	R18	SELLING et al., "Genomic RNA of an insect virus directs synthesis of infectious virions in plants", <i>PNAS</i> (1990), 87: 434-438	
	R19	TIMPE and KUHNE, "In Vitro transcript of a full-length cDNA of a naturally deleted RNA2 of barley mild mosaic virus (BaMMV) replicate in BaMMV-infected plants", <i>J. of General Virology</i> (1995), 76: 2619-2623	
	R20	TÖPFER et al., "A set of plant expression vectors for transcriptional and translational fusions", <i>Nucleic Acids Res.</i> (1987), 15: 6890	
	R21	VAN DER VOSSEN et al., "The 5' terminal sequence of Alfalfa mosaic virus RNA 3 is dispensable for replication and contains a determinant for symptom formation", <i>Virology</i> (1998), 221: 271-280	
	R22	ZHOU and JACKSON, "Analysis of cis-acting elements for replication of barley stripe mosaic virus RNA", <i>Virology</i> (1996), 219: 150-160	
	R23	PÖLO and DUBENSKY, "DNA vaccines with a kick", <i>Nature Biotech.</i> (1998), 16: 517-518	
	R24	PRICE et al., "Complete replication of an animal virus and maintenance of expression vectors derived from it in <i>Saccharomyces cerevisiae</i> ", <i>PNAS</i> (1998), 93: 9465-9470	
	R25	RASOCHOVA et al., "The Satellite RNA of barley yellow dwarf virus-RPV is supported by boot western yellows virus in Dicotyledonous Protoplasts and Plants", <i>Virology</i> (1997), 231: 182-191	
V	R26	SACHER et al., "Hybrid bromo mosaic virus RNAs express and are packaged in tobacco mosaic virus coat protein <i>In vivo</i> ", <i>Virology</i> (1988), 167: 15-24	

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/053 (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PFO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4 of 4

*Complete if Known*

Application Number	10/609,027
Filing Date	June 26, 2003
First Named Inventor	Lada Rasochova
Group Art Unit	1638
Examiner Name	(not yet assigned)
Attorney Docket Number	WARF-100XCD1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
BB	R27	KASHIWAZAKI <i>et al.</i> , "Nucleotide sequence of barley yellow mosaic virus RNA1: a close evolutionary relationship with potyviruses", <i>J. of General Virology</i> (1990), 71: 2781-2790		
	R28	KASHIWAZAKI <i>et al.</i> , "Nucleotide sequence of barley yellow mosaic virus RNA2", <i>J. of General Virology</i> (1991), 72: 995-999		
	R29	KIKKERT, "The biolistic PDS 1000/He device", <i>Plant Cell Tiss. and Org. Cult.</i> (1993), 33: 221-226		
	R30	MORI <i>et al.</i> , "Infectivity of plasmids containing brom mosaic virus cDNA linked to the cauliflower mosaic virus 3SS RNA promoter", <i>J. of Gen. Virology</i> (1991), 72: 243-246		
	R31	MORI <i>et al.</i> , "Expression of brom mosaic virus-encoded replicase genes in transgenic tobacco plants", <i>J. of Gen. Virology</i> (1992), 73: 169-172		
	R32	NEELEMAN <i>et al.</i> , "Infection of tobacco with alfalfa mosaic virus cDNAs sheds light on the early function of the coat protein", <i>Virology</i> (1993), 196: 883-887		
	R33	PACHA and AHLQUIST, "Use of bromovirus RNA3 hybrids to study template specificity in viral RNA amplification", <i>J. of Virology</i> (1991), 65: 3693-3703		
	R34	PETTY and JACKSON, "Mutational analysis of barley stripe mosaic virus RNA beta", <i>Virology</i> (1990), 179: 712-718		
	R35	CROOKE, "Antisense Research and Application", <i>Basic Principles of Antisense Therapeutics</i> (1998), chapter 1		
	R36	BRANCH, "A good antisense molecule is hard to find", <i>TIBS</i> (1998), 45-50		
▼	R37	PALU <i>et al.</i> , "In pursuit of new developments for gene therapy of human diseases", <i>J. of Biotech.</i> (1999), 68: 1-13		
	R38			
	R39			

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.